RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
Bryan Oronsky , Ramasamy Paulmurugan , Kira Foygel , Jan Scicinski
Expert Opinion on Investigational Drugs 26 ( 1) 109 -119
40
2017
A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome.
Christina E. Brzezniak , Nicole Vietor , Patricia E. Hogan , Bryan Oronsky
Case Reports in Oncology 10 ( 1) 321 -324
2
2017
Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report.
Christina Brzezniak , Bryan Oronsky , Corey A. Carter , Bennett Thilagar
Case Reports in Oncology 10 ( 1) 252 -257
3
2017
RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.
Christina Brzezniak , Bryan Oronsky , Jane Trepel , Thomas A. Summers Jr.
Case Reports in Oncology 10 ( 1) 276 -280
3
2017
The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer.
Giuseppe Giaccone , Ariel Lopez-Chavez , Corey A. Carter
Current opinion in investigational drugs 10 ( 12) 1305 -1314
47
2009
RRx-001 Reset: Chemoresensitization via NO-Mediated M1 Macrophage Repolarization
Jan Scicinski , Bryan Oronsky , Scott Caroen , Pedro Cabrales
Nitric Oxide (Donor/Induced) in Chemosensitizing#R##N#Volume 1 35 -56
2017
Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors.
Corey A. Carter , Giuseppe Giaccone
Current Opinion in Oncology 24 ( 2) 123 -129
23
2012
Survival and Racial Differences of Non-Small Cell Lung Cancer in the United States Military
Christina Brzezniak , Sacha Satram-Hoang , Hans-Peter Goertz , Carolina Reyes
Journal of General Internal Medicine 30 ( 10) 1406 -1412
16
2015
HER2 Mutations in Non–Small-Cell Lung Cancer Can Be Continually Targeted
Ronan J. Kelly , Corey A. Carter , Giuseppe Giaccone
Journal of Clinical Oncology 30 ( 26) 3318 -3319
27
2012
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001
Bryan Oronsky , Scott Caroen , Karen Zeman , Mary Quinn
Clinical Medicine Insights: Oncology 10 ( 10) 105 -108
10
2016
Integrated proteogenomic analysis of metastatic thoracic tumors identifies APOBEC mutagenesis and copy number alterations as drivers of proteogenomic tumor evolution and heterogeneity
Nitin Roper , Shaojian Gao , Tapan K. Maity , A. Rouf Banday
bioRxiv 301390
2018
Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.
Bryan Oronsky , Eilleen S. Y. Ao-Ieong , Ozlem Yalcin , Corey A. Carter
Molecular Pharmaceutics 16 ( 7) 2929 -2934
4
2019
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor.
Corey A. Carter , Aiste Degesys , Bryan Oronsky , Jan Scicinski
Case Reports in Oncology 8 ( 3) 461 -465
12
2015
RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.
Christina Brzezniak , Bruno A. Schmitz , Paul G. Peterson , Aiste Degesys
Case Reports in Oncology 9 ( 1) 45 -50
10
2016
Dysphonia after Bevacizumab Rechallenge: A Case Report.
Corey A. Carter , Scott Z. Caroen , Arnold L. Oronsky , Bryan T. Oronsky
Case Reports in Oncology 8 ( 3) 423 -425
5
2015
Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.
Corey A. Carter , Bryan Oronsky , Scott Caroen , Jan Scicinski
Respiratory medicine case reports 18 62 -65
8
2016
Molecular targets in the treatment of non-small-cell lung cancer: is there hope on the horizon?
Corey A. Carter , Joel Anthony Nations , Angeline Lazarus
Postgraduate Medicine 126 ( 7) 139 -148
2
2014
Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)
Christine M. Lovly , Jeffrey R. Infante , George R. Blumenschein , Karen Reckamp
Cancer Research 76
1
2016
Activation of Prostate-Specific Antigen Precursor (pro-PSA) by Prostin, a Novel Human Prostatic Serine Protease Identified by Degenerate PCR†,‡
Thomas K. Takayama , Corey A. Carter , Ta Deng
Biochemistry 40 ( 6) 1679 -1687
68
2001
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Arun Rajan , Corey A. Carter , Ronan J. Kelly , Martin Gutierrez
Clinical Cancer Research 18 ( 8) 2344 -2351
130
2012